Researchers called brick-and-mortar weight-loss clinics and medical spas in West Virginia and Oklahoma from August through October 2025. The July 2026 study analyzed 75 businesses that confirmed they offered compounded GLP-1s. The findings describe those businesses and the suppliers they named during the survey period.[1]
What the clinics reported
Of the 75 businesses, 42 (56%) reported offering compounded GLP-1s with B vitamins, and seven (9.3%) reported offering oral or sublingual formulations. The researchers contacted businesses by phone and recorded what staff said they offered.[1] Our review of what online GLP-1 sellers disclose covers a separate sample of storefronts.
What public records showed about the suppliers
The calls identified 24 suppliers. Researchers analyzed 23 after excluding one supplier whose dispensing location they could not identify. Of those 23, 22 held state licenses. Researchers could verify sterile compounding license status for 21 of those 22, and four of the 21 (19%) lacked that license as of December 2025.[1]
Three of the 22 state-licensed facilities (13.6%) had faced state pharmacy board action since 2023. One of the 23 facilities received two FDA warning letters in that period. The guide to 503A pharmacies and 503B outsourcing facilities explains why a state license and federal registration answer different questions.[1]
How to interpret added ingredients
A separate 2026 paper described a February–March 2025 search for compounded products that differed from commercially available versions. It identified 33 products, 48% of which combined semaglutide or tirzepatide with another ingredient. The authors found little evidence to justify adding nutrients or docusate to those injections.[2]
The regulatory guide on compounded tirzepatide after the shortage explains the rules for copies of approved drugs. FDA says that under section 503A, a prescriber must determine and document a significant difference for an identified patient when relying on that exception. Adding a vitamin alone does not establish that difference. Section 503B has separate requirements for outsourcing facilities.[4]
For readers comparing a prescription that includes a GLP-1 mixed with vitamin B12, the specific drug and formulation matter. In a laboratory study, Eli Lilly researchers found a previously uncharacterized impurity in tested compounded tirzepatide products containing certain forms of B12. The clinical effects of the impurity remain unknown.[3]
Ask the prescriber or dispensing pharmacy to name the pharmacy, confirm its exact location, and list the ingredients in the prescribed formulation. Those details let you check the facility’s current license and distinguish quotes for different formulations.